Loxo Oncology Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Loxo Oncology are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Loxo Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Loxo Oncology is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Loxo |
Loxo Oncology Relative Risk vs. Return Landscape
If you would invest (100.00) in Loxo Oncology on January 25, 2024 and sell it today you would earn a total of 100.00 from holding Loxo Oncology or generate -100.0% return on investment over 90 days. Loxo Oncology is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Loxo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Loxo Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Loxo Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Loxo Oncology, and traders can use it to determine the average amount a Loxo Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| LOXO |
Based on monthly moving average Loxo Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Loxo Oncology by adding Loxo Oncology to a well-diversified portfolio.
Loxo Oncology Fundamentals Growth
Loxo Stock prices reflect investors' perceptions of the future prospects and financial health of Loxo Oncology, and Loxo Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Loxo Stock performance.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.0059 | |||
| Profit Margin | (43.49) % | |||
| Operating Margin | (50.33) % | |||
| Current Valuation | 6.56 B | |||
| Shares Outstanding | 30.75 M | |||
| Price To Earning | (20.33) X | |||
| Price To Book | 18.92 X | |||
| Price To Sales | 49.84 X | |||
| Revenue | 144.8 M | |||
| EBITDA | (147.98 M) | |||
| Cash And Equivalents | 622 M | |||
| Cash Per Share | 3.71 X | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 12.50 X | |||
| Cash Flow From Operations | 234.3 M | |||
| Earnings Per Share | (2.09) X | |||
| Total Asset | 157.46 M | |||
| Retained Earnings | (82.93 M) | |||
| Current Asset | 156.64 M | |||
| Current Liabilities | 2.85 M |
Things to note about Loxo Oncology performance evaluation
Checking the ongoing alerts about Loxo Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Loxo Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Loxo Oncology is not yet fully synchronised with the market data | |
| Loxo Oncology has some characteristics of a very speculative penny stock | |
| Loxo Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 144.8 M. Net Loss for the year was (62.98 M) with loss before overhead, payroll, taxes, and interest of (118.74 M). | |
| Over 93.0% of the company shares are owned by institutional investors |
- Analyzing Loxo Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Loxo Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Loxo Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Loxo Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Loxo Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Loxo Oncology's stock. These opinions can provide insight into Loxo Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Loxo Stock
If you are still planning to invest in Loxo Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Loxo Oncology's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |